StreetAlpha.app
Home › Stocks › MPLT

MapLight Therapeutics, Inc. (MPLT)

Healthcare
$5.94
▼ −7.48%
LAST CLOSE · NOV 20

MapLight Therapeutics develops treatments for central nervous system disorders, with candidates in clinical trials for schizophrenia and autism. It last closed at $5.94 on Nov 20, down 7.48% on the day. The next earnings report for MPLT is expected around Thu, Mar 25, 2027. For the quarter ended Sep 2026, MPLT reported EPS of -$0.97. Over its last 6 reports the stock moved an average of 4.6% the session after earnings. Over the last 12 months MPLT insiders bought $66.2M of stock on the open market and sold $30.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is MPLT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MPLT.

Key Stats

Last 12 months
Results
Net income
−$252.0M
EPS (diluted)
$83.54
Free cash flow
−$179.0M
Balance sheet
Cash & equivalents
$55.6M
At Sep 30
Shareholder equity
$445.8M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$77.6M−$77.6MFY2024FY2025: −$161.2M−$161.2MFY2025

From MPLT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · Time not announced
Reported EPS
-$0.97
Quarter ended Sep 2026
Year ago EPS
-$37.18
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$28.01Dec '24Mar 2025: -$29.33Mar '25Jun 2025: -$39.11Jun '25Sep 2025: -$37.18Sep '25Dec 2025: $87.14Dec '25Mar 2026: -$1.34Mar '26Jun 2026: -$1.32Jun '26Sep 2026: -$0.97Sep '26Latest -$0.97
Revenue by quarter
Not enough quarters on file yet.
How MPLT moved after its last 6 reports
Average move the session after a report ±4.6%
Nov 16, 2026Time not announced−4.8%
Aug 13, 2026After the close+1.5%
May 14, 2026After the close−1.9%
Mar 26, 2026Time not announced+6.0%
Jan 9, 2026Time not announced+4.8%
Dec 4, 2025Time not announced+8.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MPLTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MPLT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MPLT

Technical Analysis

MPLT · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 19% below its 20 day and 45% below its 50 day average. It is 232% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 30), oversold. The nearest support is the 52 week low at $5.92, and the nearest resistance the Pivot at $6.12.

Short trendBearish
Long trendBearish
MomentumFading
StretchOversold
VolatilityNormal, 9.7%/day
Key levels
$40.4352 week high+580.6%
$19.70200 day average+231.6%
$14.53100 day average+144.6%
$8.6350 day average+45.3%
$7.80Swing high (Nov 11)+31.3%
$7.0820 day average+19.2%
$6.31Pivot R1+6.2%
$6.12Pivot+3.0%
$5.94Last close
$5.9252 week low−0.3%
$5.75Pivot S1−3.2%
Indicators
RSI (14)29.94Oversold below 30Oversold
MACD-0.65Above its signal lineBullish
Stochastic18.4Near the bottom of its rangeOversold
ADX (14)45.3Strong downtrend
Williams %R-99.2Oversold below −80, overbought above −20Oversold
CCI (20)-149.5Oversold below −100, overbought above 100Oversold
Rate of change−14.3%Change over 10 sessionsBearish
ATR (14)$0.58Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MPLT

What happened before

See how MPLT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for MPLTHow many large options trades hit MPLT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

MPLT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●60 buying vs 53 selling
  • ▲Held by funds +11.5 pts
  • ▼Funds holding -9
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding98107−8.4%
In funds' top 1038−62.5%
Held by funds73.3%61.9%+11.5 pts
New / increased20 / 4037 / 21+3.4%
Reduced / sold out26 / 2729 / 10+35.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MPLT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MPLT Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$66.2M5 buys · 4 insiders
Sold$30.2M39 sales · 8 insiders
66% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $65.5M between Jul 28 and Aug 14.
2026-01 sold $636K2026-02 bought $694K2026-02 sold $732K2026-04 sold $4.7M2026-05 sold $11.5M2026-07 bought $15.5M2026-07 sold $11.2M2026-08 bought $50.1M2026-08 sold $277K2026-09 sold $193K2026-10 sold $1.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 15Christopher A. KroegerCEOSale73,691$8.08$595K
Oct 15Jonathan GillisCAO and Interim CFOSale10,167$8.08$82K
Oct 15James Woodruff LillieChief Scientific OfficerSale11,513$8.08$93K
Oct 15Kristopher HansonGeneral CounselSale9,020$8.08$73K
Oct 15Erin Pennock FoffChief Medical OfficerSale15,355$8.08$124K
Oct 15Anatol KreitzerChief Discovery OfficerSale12,248$7.84$96K
Every insider buy and sale for MPLT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MPLT insider trades →

From SEC Form 4 filings by MPLT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MPLT is in one of them and how their past MPLT trades turned out.

MPLT in the AI portfolios
Loading…

MPLT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MPLT in an article yet. Here's the latest on the wider market.

MPLT in the news

About MapLight Therapeutics

MapLight Therapeutics is a biopharmaceutical company based in Redwood City, California, that develops medicines for disorders of the central nervous system. Its main candidate, ML-007C-MA, is in clinical trials for schizophrenia and for psychosis linked to Alzheimer's disease. The company is also testing ML-004 for social communication difficulties in autism and has several preclinical programs. Its treatments are aimed at patients and the prescribers who care for them.

Headquarters
Redwood City, CA